TenNor Therapeutics and 32 Greater China deals worth almost $736m

TenNor Therapeutics, a clinical-stage biotech firm specialised in the discovery and development of new drug products targeting bacterial infection and metabolic diseases, has secured 300 million yuan ($42.1 million) in the first close of its Series E round.